Kristin Yarema
CIK 1803794 · Chief Executive Officer · last filed 2026-03-18
Kristin Yarema is a Chief Executive Officer who has filed 11 SEC Form 4 insider transactions across 3 companies since 2020. The most recent filing, for IMA, was dated Mar 18, 2026. Across all open-market trades the lifetime net is +$489.3K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.26M
3
11
$489.3K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMA | Chief Executive Officer | 85,400 | $5.62 | $479.9K | $0 | 2 | 2026-03-18 |
| Poseida Therapeutics, Inc. (PSTX) Delisted | President and CEO | 0 | $9.50 | $0 | $0 | 3 | 2025-01-08 |
| ATRA | Chief Commercial Officer | 171,415 | $10.41 | $1.78M | $489.3K | 6 | 2022-03-03 |
Recent Filings
11 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-18 | IMA | Grant (A) | +85,400 | $0 | EDGAR |
| 2025-07-30 | IMA | Grant (A) | — | $0 | EDGAR |
| 2025-01-08 | Poseida Therapeutics, Inc. (PSTX) Delisted | Mixed | −615,836 | $0 | EDGAR |
| 2024-01-04 | Poseida Therapeutics, Inc. (PSTX) Delisted | Grant (A) | +250,000 | $0 | EDGAR |
| 2023-04-12 | Poseida Therapeutics, Inc. (PSTX) Delisted | Grant (A) | +356,836 | $0 | EDGAR |
| 2022-03-03 | ATRA | Grant (A) | +45,533 | $0 | EDGAR |
| 2021-06-15 | ATRA | Buy (P) | +34,354 | $500.4K | EDGAR |
| 2021-05-20 | ATRA | Sell (S) | −761 | -$11.1K | EDGAR |
| 2021-03-03 | ATRA | Grant (A) | +35,021 | $0 | EDGAR |
| 2020-03-03 | ATRA | Grant (A) | +55,000 | $0 | EDGAR |